Overview: Scl-70 Antibody TestIntroduction: The Scl-70 Antibody Test detects Scl-70 antibodies to diagnose scleroderma, causing skin tightening. Aligned with 2023 ACR guidelines, it uses immunoassays for high specificity, supporting autoimmune screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in immunology for patients with suspected systemic sclerosis.
Other Names: Scl-70 Antibody Assay, Anti-Topoisomerase I Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: Scl-70 antibody testing began in the 1970s with scleroderma research. Immunoassay methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects Scl-70 antibodies to diagnose scleroderma, guides treatment, and evaluates patients with skin tightening.
Test Parameters: 1. Scl-70 Antibodies
Pretest Condition: No fasting required. Collect serum or saliva. Report history of skin tightening or autoimmune symptoms.
Specimen: Serum (SST, 2-5 mL), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document skin tightening, Raynaud's phenomenon, or family history of scleroderma. Include current medications, especially immunosuppressants.
Consent: Written consent required, detailing the tests purpose, scleroderma implications, and risks of sample collection.
Procedural Considerations: Uses enzyme-linked immunosorbent assay (ELISA) to detect Scl-70 antibodies. Results are available in 1-2 days, supporting clinical decisions. Performed in laboratories, often for scleroderma diagnosis.
Factors Affecting Result Accuracy: Sample hemolysis or improper storage can affect results. Cross-reactivity with other autoantibodies may reduce specificity.
Clinical Significance: Positive Scl-70 antibodies confirm systemic sclerosis, guiding immunosuppressive therapy. Negative results may require anti-centromere antibody testing.
Specialist Consultation: Consult a rheumatologist for result interpretation and treatment planning.
Additional Supporting Tests: Anti-centromere antibodies, ANA, or skin biopsy to confirm scleroderma diagnosis.
Test Limitations: Non-specific for certain autoimmune conditions; clinical correlation is needed. Sample quality affects sensitivity.
References: ACR Scleroderma Guidelines, 2023; Arthritis & Rheumatology, Steen VD, 2022.
